Articles tagged with Pancreatic Tumors
Researchers at Johns Hopkins Medicine discovered a potential therapy strategy by restoring lost microRNAs in human pancreatic tumor cells. The study found that these microRNAs put brakes on tumors when the KRAS gene is mutated, a common event in pancreatic cancer.
A new study found that many pancreatic tumors are slow-growing, taking nearly 20 years to become lethal after the first genetic perturbations appear. This challenges previous theories and suggests a potential window of opportunity for early diagnosis and treatment.
A Phase III study showed that everolimus improves progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. The drug has antitumor efficacy in addition to currently available agents, offering new treatment options for rare cancers.
Individual cancer-causing mutations have a minor effect on tumor growth, increasing cell division rates and contributing to the accumulation of multiple mutations. The research suggests that significant tumor growth requires the slow accumulation of multiple mutations over years, explaining why many cancer-driving mutations are needed.
Researchers found that bacteria can selectively target and kill cancer cells in tumors of a specific medium size, leading to complete tumor disappearance. The therapy works by germinating and growing bacterial spores in the oxygen-free tumor centers, causing damage to surrounding tumor cells.
A six-gene signature associated with metastatic disease has been identified in patients with pancreatic cancer, enabling earlier prediction of survival prognosis and potential therapeutic targets. This finding may inform treatment decisions and improve patient outcomes.
Segmental duodenectomy (SD) is a reliable and curative option for most duodenal gastrointestinal stromal tumors, offering long-term disease-free survival. In contrast, pancreaticoduodenectomy (PD) remains a good alternative for tumors in the vicinity of the pancreas.
Researchers discover that toll-like receptors (TLRs) such as TLR4 are overexpressed in pancreatic ductal adenocarcinoma (PDAC), promoting tumor progression. The study also found a positive correlation between TLR4 and HIF-1α expression, suggesting TLR4 as a potential marker for PDAC progression.
Researchers at UNC identified a molecular marker of pancreatic cancer that may help diagnose the disease earlier. A specific form of a protein called palladin is produced in large amounts in tumor-associated fibroblasts surrounding a pancreatic tumor, making it a potential diagnostic tool.
A systematic review of 111 studies involving 4,394 patients found that a third could undergo resection after neoadjuvant therapy, with similar survival rates to those judged resectable before treatment. The study suggests including locally advanced/unresectable tumors in neoadjuvant protocols.
Solid pseudopapillary tumors of the pancreas are rare indolent neoplasms typically occurring in young females. The symptoms were non-specific and nearly one-third of patients were asymptomatic, making misdiagnosis common. Extended resections can potentially cure SPTs, with a favorable prognosis even after recurrence or metastasis.
Researchers at UT Southwestern Medical Center found that a synthetic compound called JP1201, mimicking the action of a 'death-promoting' protein, can enhance chemotherapy's efficacy and prolong life in mice with pancreatic cancer. The study demonstrates promising results for potential therapies against this devastating disease.
Solid-pseudopapillary neoplasm (SPN) of the pancreas is characterized by cystic-solid tumors in young women, often with hemorrhage and necrosis. Immunohistochemistry helps differentiate it from pancreatic endocrine tumor (PET), which harbors distinct genetic mutations.
Researchers at the Mayo Clinic have found that PKC-iota is over-produced in pancreatic cancer and is linked to poor patient survival. Genetically inhibiting PKC-iota led to a significant decrease in pancreatic tumor growth and spread in laboratory animals.
Researchers at University of California, San Diego have identified a signaling protein called RON that helps pancreatic cancer cells survive and resist chemotherapy. The study provides new insights into pancreatic cancer development and suggests combining RON-targeted therapy with other treatments to combat tumor resistance.
Researchers found that tumor-associated macrophages produce high levels of proteases cathepsin B and S, enhancing tumor growth and invasion. Interleukin-4 stimulation by tumors stimulates increased Cts B and S activity, providing a potential therapeutic target.
Researchers utilize zebrafish to study human cancer, leveraging transplantable tumors, genetic models, and transgenic fish to understand tumor development and metastasis. The special issue presents innovative approaches for modeling human cancer in zebrafish.
Researchers used EUS with contrast-enhanced harmonic imaging to diagnose small pancreatic carcinomas. Periodic follow-ups revealed accurate diagnosis of disease progression in patients with branch duct intraductal papillary mucinous neoplasm (IPMN).
Researchers have identified a peptide called iRGD that specifically targets and penetrates cancerous tumors, delivering diagnostic particles and medicines. This breakthrough could improve cancer treatment and reduce side effects.
A new study found that targeted heat therapy significantly improves overall survival and reduces cancer recurrence in patients with locally advanced soft tissue sarcomas. The treatment, which involves heating the tumor to kill cancer cells, also makes chemotherapy more effective and improves blood flow.
Researchers used MDCT to assess IPMN image characteristics, identifying larger cystic lesions and ducts in malignant cases. The combined-type IPMNs had a higher rate of malignancy than other types, while tumors with mural nodules showed a significantly higher incidence of malignancy.
Researchers induced pathological damage to a normal pancreas with an immune adjuvant and found that it triggered a strong anti-self response, which suppressed autoimmunity. The study highlights the complexity of immune responses in different organs and may lead to new therapeutic approaches for cancer treatment
A study published in Clinical Cancer Research found that a blood-flow metabolism mismatch in pancreatic tumors predicts poor patient outcome. The researchers used PET imaging to measure blood flow and glucose consumption, revealing a correlation between decreased blood flow and malignant tumors.
Researchers propose a novel two-agent combination therapy that selectively kills tumors while sparing healthy cells. The approach leverages the frequent absence of methylthioadenosine phosphorylase in various lethal cancers, allowing for increased doses and reduced toxic side effects.
Aminoguanidine reduces pancreatic tumor growth, delays metastasis appearance, and extends mouse survival. The compound's mechanism involves inhibiting nitric oxide synthase, anti-angiogenic effects, and reduced antioxidant enzyme expression.
Imaging findings on MDCT suggest a higher risk of recurrence and metastasis in solid pseudopapillary tumors of the pancreas. The study found that larger tumor size and specific imaging features were associated with increased vascular invasion and capsular disruption, indicating malignant potential.
A pioneering surgical technique developed in Spain has successfully removed benign tumors from the pancreas using laparoscopic central pancreatectomy, preserving a large part of the gland. The procedure reduces complications, hospitalization periods, and risk of post-operative diabetes.
Researchers at Stanford University School of Medicine identified a key protein involved in pancreatic cancer growth. Blocking its expression slowed or prevented tumor growth in mice and made cultured cancer cells vulnerable to low oxygen conditions.
Researchers at M. D. Anderson Cancer Center identified new biomarkers for treatment response in pancreatic cancer, associating mismatch repair genes with tumor resectability and overall survival. The study found that variations in DNA repair genes can predict patient outcomes, enabling doctors to choose the best therapy.
Scientists have developed a new imaging agent using bevacizumab, which surpasses existing methods in detecting tumors. The compound successfully targets cancer cells and provides clearer images of tumors, enabling earlier stages of detection and fewer false positives.
The breast cancer incidence in China is expected to increase due to lifestyle changes and adoption of Western lifestyles. Researchers predict a total of 2.5 million cases by 2012, with modifications to lifestyle and reproductive risk factors potentially preventing 270,000 cases.
Research isolated a subset of pancreatic cancer cells expressing CD44 and CD24, which exhibit lower proliferative index and faster tumor growth rate. Further purification is needed to understand their biological behaviors.
A new chemotherapy drug combination has shown excellent results in a phase II trial, extending median survival time in patients with inoperable pancreatic cancer by up to 6.4 months compared to standard therapy. The treatment, EndoTAG-1, destroys new blood vessels around tumors, improving patient outcomes.
A new technique using flexible gastrointestinal endoscope with miniature ultrasound transducer can directly inject cancer fighting agents into tumors, avoiding normal tissue damage. This approach, combined with systemic chemotherapy, shows promise in treating certain cancers.
STDs like genital herpes and chlamydia increase the risk of becoming infected with HIV due to inflammation in Langerhans cells. Anti-inflammatory therapies might help prevent HIV transmission by modulating the immune response.
Researchers report that endoscopic ultrasound (EUS) is highly accurate in diagnosing pancreatic neoplasms, with a 99.1% accuracy rate. EUS-FNA also shows excellent results, with 88.8% sensitivity and 100% specificity, making it an ideal next step for patients with ambiguous imaging findings.
Researchers from Fred Hutchinson Cancer Research Center identified five proteins that may be useful tools in detecting early-stage pancreatic tumors. The panel of proteins discriminated between pancreatic cancer cases and controls in blood specimens, suggesting a potential role in early detection.
Scientists have discovered a molecular marker, RIP140, that controls both metabolic processes and inflammatory responses in liver cells of mice with cancer. By switching off this molecule, the lipid balance of the liver normalized within a few days, suggesting its role in causing fatty liver in affected patients.
Researchers discovered a molecular pathway underlying low-grade forms of brain tumor known as astrocytoma, suggesting new therapeutic targets. Additionally, studies revealed that microRNAs regulate female mouse fertility by controlling the functioning of the corpus luteum, which is essential for pregnancy.
Researchers have identified a master regulator of EMT that consists of a specific group of microRNAs called miR-200. Introducing miR-200 into late cancer cells may provide a new form of treatment by preventing cells from going through EMT and becoming more invasive.
A rare pancreatic tumor was treated with surgery and chemotherapy, resulting in long-term stability. The case report reviews the impact of aggressive surgery on prognosis.
A case report describes a patient with colonic duplication that mimicked a pancreatic tumor, emphasizing the importance of considering intestinal duplication in abdominal mass diagnoses. Histopathological examination confirmed the diagnosis after distal pancreatectomy.
A case report describes a patient with a benign bile duct tumor, adenomyoma, which was successfully treated with pancreaticoduodenectomy. The study highlights the importance of accurate diagnosis and treatment to avoid unnecessary surgery.
A new study by Saint Louis University researchers found a striking correlation between patient prognosis and tumor size at diagnosis. Patients with tumors under 20mm had the highest median survival rates, but only accounted for 18% of cases.
A novel technique of image-guided fine-needle aspiration (FNA) using endoscopic ultrasound (EUS) guidance is introduced for accurate preoperative diagnosis of pancreatic solid pseudopapillary tumors. This method helps differentiate SPTP from other pancreatic neoplasms with different biologic behavior and treatment.
Recent research evaluates the progress made to date in diagnosing and treating pancreatic cancer, highlighting promising new applications of technology that will improve survival rates. The studies also identify key predictors of malignancy, including age, gender, symptoms, and radiographic features.
A recent study evaluated the incidence of malignancy in small pancreatic tumors and identified predictors such as age, gender, symptoms, and radiographic features. The findings suggest that very small tumors with no other symptoms or radiographic indicators have a low risk of malignancy.
A study from the University of Pittsburgh Cancer Institute found that triphala extracts can prevent or slow pancreatic cancer tumor growth in mice by inducing apoptosis. The herb was shown to activate tumor-suppressor genes, supporting the generation of proteins that promote cell death in cancer cells.
Researchers have successfully targeted the blood vessels that feed tumors, providing a new approach to treating cancer. The study used an antibody called J591 that selectively targets prostate-specific membrane antigen (PSMA) on tumors and not healthy tissues.
Researchers identified a new route to cancer treatment by exploiting mutations that control cell movement. Understanding the collaboration between Ras and p53 genes may lead to novel therapeutic targets like Rho proteins.
Researchers at Vanderbilt University Medical Center have developed a new animal model for pancreatic cancer that exhibits aggressive characteristics similar to human tumors. The genetically-engineered mice can be used to investigate targeted drug therapies and identify potential screening methods for early detection.
Researchers at SUNY Downstate Medical Center have found that PNC-28, a human protein, can destroy pancreatic tumor cells in animals without harming healthy cells. The study's results are encouraging and suggest PNC-28 may be an effective agent in treating cancers, particularly when delivered directly to the tumor.
Researchers discovered how Myc oncoprotein drives tumor angiogenesis in pancreatic cancer by inducing IL-1beta expression. Blocking IL-1beta activity can thwart tumor angiogenesis, offering experimental evidence for cancer drug therapies targeting this pathway.
Researchers found that pancreatic tumors surround themselves with regulatory T cells to avoid detection by the immune system. Depleting these cells slowed tumor growth and increased survival time in mice. The study suggests a potential way to block tumor recruitment of regulatory T cells and revive cancer immunotherapy.
Researchers discovered capsaicin significantly reduces tumor size and induces apoptosis in human pancreatic cancer cells, with no harm to normal pancreatic tissue. The compound's potential use as a novel agent for prevention and treatment of pancreatic cancer is being explored.
The FACTT technology has a sensitivity five orders of magnitude greater than ELISA, allowing for the detection of rare molecules at early stages. This new method holds promise for detecting abnormalities in diseases such as breast, ovarian, and pancreatic cancer.
A new clinical trial at Northwestern Memorial Hospital aims to evaluate the effectiveness of combining chemotherapy and radiation therapy with Avastin in reducing tumor size and increasing survival rates. The two-year study will enroll 40 participants with localized pancreatic cancer.
Researchers have identified the stage-specific roles of individual cathepsins in tumorigenesis, revealing that inhibiting cathepsin B, L, and S suppresses cancer development. The study found that these cathepsins promote tumor invasion by cleaving E-cadherin.
Researchers developed a new treatment that reverses traditional treatment steps, reducing tumor size and increasing surgical removal options. The treatment has shown significant success in shrinking tumors, with no progression or recurrence observed after surgery.
A phase II clinical trial evaluated SU11248 for carcinoid and pancreatic islet cell tumors, demonstrating 80% stabilization of disease progression. The drug hinders key proteins and receptors that cancer cells rely on to thrive.